Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner.

Gallezot JD, Zheng MQ, Lim K, Lin SF, Labaree D, Matuskey D, Huang Y, Ding YS, Carson RE, Malison RT.

J Nucl Med. 2014 Jun;55(6):960-6. doi: 10.2967/jnumed.113.132928. Epub 2014 Apr 14.

2.

Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M.

Biol Psychiatry. 2010 Aug 15;68(4):392-9. doi: 10.1016/j.biopsych.2010.04.038.

PMID:
20599188
3.

In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.

Girgis RR, Xu X, Miyake N, Easwaramoorthy B, Gunn RN, Rabiner EA, Abi-Dargham A, Slifstein M.

Neuropsychopharmacology. 2011 Mar;36(4):887-95. doi: 10.1038/npp.2010.228. Epub 2010 Dec 22.

4.

High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.

Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA.

Biol Psychiatry. 2006 Mar 1;59(5):389-94. Epub 2005 Dec 20.

PMID:
16373068
5.

Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.

Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA.

J Neurochem. 2006 May;97(4):1089-103. Epub 2006 Apr 5.

6.

Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.

Narendran R, Frankle WG, Mason NS, Laymon CM, Lopresti BJ, Price JC, Kendro S, Vora S, Litschge M, Mountz JM, Mathis CA.

Synapse. 2009 Jul;63(7):574-84. doi: 10.1002/syn.20633.

7.

The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.

Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S, Wilson AA, Kapur S.

Arch Gen Psychiatry. 2009 Jun;66(6):606-15. doi: 10.1001/archgenpsychiatry.2009.43.

PMID:
19487625
8.

Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo.

Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA.

Synapse. 2012 Jun;66(6):489-500. doi: 10.1002/syn.21535. Epub 2012 Feb 24.

PMID:
22213512
9.

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.

Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S, Mizrahi R.

J Psychiatry Neurosci. 2013 Mar;38(2):98-106. doi: 10.1503/jpn.110181.

10.

Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain.

Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA.

J Cereb Blood Flow Metab. 2007 Apr;27(4):857-71. Epub 2006 Oct 11.

11.

Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.

Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A.

Neuropsychopharmacology. 2014 Nov;39(12):2769-76. doi: 10.1038/npp.2014.125. Epub 2014 May 30.

12.

Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S.

Hum Brain Mapp. 2008 Apr;29(4):400-10.

PMID:
17497628
13.

[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.

Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, Adams JR, Rusjan P, Houle S, Furukawa Y, Wilson AA, Boileau I.

Mov Disord. 2015 Feb;30(2):160-6. doi: 10.1002/mds.26135. Epub 2015 Jan 14.

PMID:
25641350
14.

Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.

Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M.

Synapse. 2006 Dec 1;60(7):485-95.

PMID:
16952157
15.
16.
17.

Positron emission tomography imaging of dopamine D₂/₃ receptors in the human cortex with [¹¹C]FLB 457: reproducibility studies.

Narendran R, Mason NS, May MA, Chen CM, Kendro S, Ridler K, Rabiner EA, Laruelle M, Mathis CA, Frankle WG.

Synapse. 2011 Jan;65(1):35-40. doi: 10.1002/syn.20813.

18.

Reproducibility of post-amphetamine [11C]FLB 457 binding to cortical D2/3 receptors.

Narendran R, Himes M, Mason NS.

PLoS One. 2013 Sep 30;8(9):e76905. doi: 10.1371/journal.pone.0076905. eCollection 2013.

19.

Mathematical modelling of [¹¹C]-(+)-PHNO human competition studies.

Searle GE, Beaver JD, Tziortzi A, Comley RA, Bani M, Ghibellini G, Merlo-Pich E, Rabiner EA, Laruelle M, Gunn RN.

Neuroimage. 2013 Mar;68:119-32. doi: 10.1016/j.neuroimage.2012.11.033. Epub 2012 Nov 30.

PMID:
23207573
20.

Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.

Abi-Jaoude E, Segura B, Obeso I, Cho SS, Houle S, Lang AE, Rusjan P, Sandor P, Strafella AP.

Hum Brain Mapp. 2015 Jul;36(7):2592-601. doi: 10.1002/hbm.22793. Epub 2015 Mar 18.

PMID:
25788222
Items per page

Supplemental Content

Write to the Help Desk